Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: Evidence for multiple receptor states

Molecular Pharmacology

Volumn 50, Issue 6, 1996, Pages 1596-1604

  Van Rampelbergh, Jean ^a   Gourlet, Philippe ^a   De Neef, Philippe ^a   Robberecht, Patrick ^a   Waelbroeck, Magali ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IODINE 125; RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CHIMERA; CHO CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENYLATE CYCLASE; AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; ENZYME ACTIVATION; IODINE RADIOISOTOPES; KINETICS; MOLECULAR SEQUENCE DATA; PLASMIDS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, PITUITARY HORMONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RECOMBINANT FUSION PROTEINS;

EID: 0030473472     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pisegna, J. R., and S. A. Wank, Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc. Natl. Acad. Sci. USA 90:6345-6349 (1993).
2. Ishihara, T., R. Shigemoto, K. Mori, K. Takahashi, and S. Nagata. Functional expression and tissue distribution of a novel receptor for vaeoactive intestinal polypeptide. Neuron 8:811-819 (1992).
3. 2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334:3-8 (1993).
4. Svoboda, M., M. Tastenoy, J. Van Rampelbergh, J.-F. Goossens, P. De Neef, M. Waelbroeck, and P. Robberecht. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205:1617-1624 (1994).
5. Christophe, J. Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochim. Biophys. Acta 1154:83-199 (1993).
6. Robberecht, P., M. Waelbroeck, P. De Neef, M. Tastenoy, P. Gourlet, J. Cogniaux, and J. Christophe. A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts. FEBS Lett. 228: 351-355 (1988).
7. Robberecht, P., P. De Neef, P. Gourlet, A. Cauvin, D. H. Coy, and J. Christophe. Pharmacological characterization of the novel helodermin/VIP receptor present in human SUP-T1 lymphoma cell membranes. Regul. Pept. 26:117-126 (1989).
8. Gourlet, P., P. De Neef, M.-C. Woussen-Colle, A. Vandermeers, M.-C. Vandermeers-Piret, P. Robberecht, and J. Christophe. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes. Biochim. Biophys. Acta 1066:245-251 (1991).
9. Spengler, D., C. Waeber, C. Pantaloni, F. Holsboer, J, Bockaert, P. H. Seeburg, and L. Journot. Differential signal transduction by five splice variants of the PACAP receptor. Nature (Lond.) 365:170-175 (1993).
10. Ciccarelli, E., J.-P. Vilardaga, P. De Neef, E. Di Paolo, M. Waelbroeck, A. Bollen, and P. Robberecht. Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regul. Pept. 54:397-407 (1994).
11. Ciccarelli, E., M. Svoboda, P. De Neef, E. Di Paolo, A. Bollen, C. Dubeaux, J.-P. Vilardaga, M. Waelbroeck, and P. Robberecht. Pharmacological properties of two recombinant splice variants of the PACAP type I receptor transfected and stably expressed in CHO cells. Eur. J. Pharmacol. 288: 259-267 (1995).
12. Robberecht, P., M.-C. Woussen-Colle, P. De Neef, P. Gourlet, L. Buscail, A. Vandermeers, M.-C. Vandermeers-Piret, and J. Christophe. The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP(1-27) and PACAP(1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranes. FEBS Lett. 286:133-136 (1991).
13. Cauvin, A., P. Robberecht, P. De Neef, P. Gourlet, A. Vandermeers, M.-C. Vandermeers-Piret, and J. Christophe. Properties and distribution of receptors for pituitary adenylate cyclase activating peptide (PACAP) in rat brain and spinal cord. Regul. Pept. 35:161-173 (1991).
14. Gourlet, P., A. Vandermeers, M.-C. Vandermeers-Piret, J. Rathé, P. De Neef, and P. Robberecht. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur. J. Pharmacol. 287:7-11 (1995).
15. Robberecht, P., P. Gourlet, P. De Neef, M.-C. Woussen-Colle, M.-C. Vandermeers-Piret. A. Vandermeers, and J. Christophe. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3,20, or 21. Mol. Pharmacol. 42:347-355 (1992).
16. Salomon, Y., C. Londos, and M. Rodbell. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58:541-548 (1974).
17. Robberecht, P., P. Gourlet, A. Cauvin, L. Buscail, P. De Neef, A. Arimura, and J. Christophe. PACAP and VIP receptors in rat liver membranes. Am. J. Physiol. 260:G97-G102 (1991).
18. Swillens, S. How to estimate the total receptor concentration when the specific radioactivity of the ligand is unknown. Trends Pharmacol. Sci. 13:430-434 (1992).
19. Vilardaga, J.-P., P. De Neef, E. Di Paolo, A. Bollen, M. Waelbroeck, and P. Robberecht. Properties of chimeric and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination. Biochem. Biophys. Res. Commun. 211:885-891 (1995).
20. Holtmann, M. H., E. M. Hadac, and L. J. Miller. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. J, Biol. Chem. 270:14394-14398 (1995).
21. De Léan, A., J. M. Stadel, and R. J. Lefkowitz. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor, J, Biol. Chem. 255:7108-7117 (1980).
22. Lee, T. W. T., M. J. Sole, and J. W. Wells. Assessment of a ternary model for the binding to agonists to neurohormonal receptors. Biochemistry 25: 7009-7020 (1986).
23. i and inositol phosphates in human neuroblastoma NB-OK-1 cells. Peptides 14:1111-1118 (1993).
24. Deutsch, P. J., and Y. Sun. The 38-amino acid form of pituitary adenylate cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth. J. Biol. Chem. 267:5108-5113 (1992).
25. Canny, B. J., S. R. Rawlings, and D. A. Leong. Pituitary adenylate cyclase-activating polypeptide specifically increases cytosolic calcium ion concentration in rat gonadotropes and somatotropes. Endocrinology 130:211-215 (1992).